Zobrazeno 1 - 10
of 379
pro vyhledávání: '"C Amrein"'
Autor:
Joan How, Siyang Ren, Jennifer Lombardi‐Story, Meghan Bergeron, Julia Foster, Phillip C. Amrein, Andrew M. Brunner, Amir T. Fathi, Hanno Hock, Anna Khachatryan, Hiroto Kikuchi, Mei Rosa Ng, Jenna Moran, Rupa Narayan, Donna Neuberg, Aura Ramos, Tina Som, Meghan Vartanian, Yi‐Bin Chen, Dan G. Duda, Gabriela S. Hobbs
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 434-442 (2022)
Abstract We conducted a single‐center, open‐label, dose escalation, and expansion phase I trial of the antiangiogenic multikinase inhibitor regorafenib in patients with advanced myeloid neoplasms. We enrolled 16 patients with relapsed/refractory
Externí odkaz:
https://doaj.org/article/b768134a01424428b03dc52b7afb2c56
Autor:
Valentina Nardi, Nora Ku, Matthew J. Frigault, Adrian M. Dubuc, Harrison Kwei Tsai, Philip C. Amrein, Gabriela S. Hobbs, Andrew M. Brunner, Rupa Narayan, Meghan E. Burke, Julia Foster, Paola Dal Cin, Marcela V. Maus, Amir T. Fathi, Hanno Hock
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 106-111 (2020)
Abstract: Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL) is a subtype of Ph-negative ALL that molecularly resembles Ph-positive ALL. It shares the adverse prognosis of Ph-positive ALL, but lacks the BCR-ABL1 fusion oncogene. I
Externí odkaz:
https://doaj.org/article/7fc7238856444e36b2853dd5b133bf4f
Autor:
Amir T. Fathi, Haesook T. Kim, Robert J. Soiffer, Mark J. Levis, Shuli Li, Annette S. Kim, Zachariah DeFilipp, Areej El-Jawahri, Steve L. McAfee, Andrew M. Brunner, Philip C. Amrein, Alice S. Mims, Laura W. Knight, Devon Kelley, AJ S. Bottoms, Lindsey H. Perry, Jonathan L. Wahl, Jennifer Brock, Elayne Breton, Dylan M. Marchione, Vincent T. Ho, Yi-Bin Chen
Publikováno v:
Clinical Cancer Research. 29:2034-2042
Purpose: Isocitrate dehydrogenase 1 (IDH1) mutations occur in 5% to 10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use in patients with IDH1-mutated AML. Patients and Methods: We conducted a multicent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6018d58039b44e1e6368f3333c96f2a6
https://doi.org/10.1158/1078-0432.ccr-23-0182
https://doi.org/10.1158/1078-0432.ccr-23-0182
Autor:
Andrew M. Brunner, Traci M. Blonquist, Gabriela S. Hobbs, Philip C. Amrein, Donna S. Neuberg, David P. Steensma, Gregory A. Abel, Amir T. Fathi
Publikováno v:
Blood Advances, Vol 1, Iss 23, Pp 2032-2040 (2017)
Abstract: Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders associated with progression to leukemia and poor survival. Clonal hematopoiesis in people without an MDS diagnosis carries an increased risk of cardiovascular deat
Externí odkaz:
https://doaj.org/article/79a1f4f592d84054b970852a59157929
Autor:
Yi-Bin Chen, Vincent T. Ho, Dylan M. Marchione, Elayne Breton, Jennifer Brock, Jonathan L. Wahl, Lindsey H. Perry, AJ S. Bottoms, Devon Kelley, Laura W. Knight, Alice S. Mims, Philip C. Amrein, Andrew M. Brunner, Steve L. McAfee, Areej El-Jawahri, Zachariah DeFilipp, Annette S. Kim, Shuli Li, Mark J. Levis, Robert J. Soiffer, Haesook T. Kim, Amir T. Fathi
Representativeness of Study Participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41242f9d5f686fdbc7c3a194abe99cc1
https://doi.org/10.1158/1078-0432.22651561.v1
https://doi.org/10.1158/1078-0432.22651561.v1
Autor:
Yi-Bin Chen, Vincent T. Ho, Dylan M. Marchione, Elayne Breton, Jennifer Brock, Jonathan L. Wahl, Lindsey H. Perry, AJ S. Bottoms, Devon Kelley, Laura W. Knight, Alice S. Mims, Philip C. Amrein, Andrew M. Brunner, Steve L. McAfee, Areej El-Jawahri, Zachariah DeFilipp, Annette S. Kim, Shuli Li, Mark J. Levis, Robert J. Soiffer, Haesook T. Kim, Amir T. Fathi
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c462541a9f1c003172c988b6c6e5ad9f
https://doi.org/10.1158/1078-0432.22651564.v1
https://doi.org/10.1158/1078-0432.22651564.v1
Autor:
Yi-Bin Chen, Vincent T. Ho, Dylan M. Marchione, Elayne Breton, Jennifer Brock, Jonathan L. Wahl, Lindsey H. Perry, AJ S. Bottoms, Devon Kelley, Laura W. Knight, Alice S. Mims, Philip C. Amrein, Andrew M. Brunner, Steve L. McAfee, Areej El-Jawahri, Zachariah DeFilipp, Annette S. Kim, Shuli Li, Mark J. Levis, Robert J. Soiffer, Haesook T. Kim, Amir T. Fathi
Purpose:Isocitrate dehydrogenase 1 (IDH1) mutations occur in 5% to 10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use in patients with IDH1-mutated AML.Methods:We conducted a multicenter, phase I tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a1db0aac1a12c611677a4617ca41ca4
https://doi.org/10.1158/1078-0432.c.6604888.v1
https://doi.org/10.1158/1078-0432.c.6604888.v1
Autor:
Yi-Bin Chen, Vincent T. Ho, Dylan M. Marchione, Elayne Breton, Jennifer Brock, Jonathan L. Wahl, Lindsey H. Perry, AJ S. Bottoms, Devon Kelley, Laura W. Knight, Alice S. Mims, Philip C. Amrein, Andrew M. Brunner, Steve L. McAfee, Areej El-Jawahri, Zachariah DeFilipp, Annette S. Kim, Shuli Li, Mark J. Levis, Robert J. Soiffer, Haesook T. Kim, Amir T. Fathi
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccfeb07ae50aeff720c8e7893ef44bfe
https://doi.org/10.1158/1078-0432.22651567.v1
https://doi.org/10.1158/1078-0432.22651567.v1
Autor:
Amir T. Fathi, Geoffrey G Fell, Areej El-Jawahri, Alexander E. Perl, Brian A. Jonas, Ajoy L. Dias, Alice S. Mims, Uma Borate, Brittany Knick Ragon, Michael R. Grunwald, Mary Linton B. Peters, Timothy A. Graubert, Philip C. Amrein, Hanno R. Hock, Andrew M. Brunner, Gabriela S. Hobbs, Rupa Narayan, Donna S. Neuberg, Ibrahim Aldoss
Publikováno v:
Blood. 140:3284-3286
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0461e29c8969a9415f041ed1cdf043c5
https://doi.org/10.1182/blood-2022-162525
https://doi.org/10.1182/blood-2022-162525
Autor:
Valentina Nardi, Steven L McAfee, Paola Dal Cin, Harrison K Tsai, Philip C Amrein, Gabriela S Hobbs, Andrew M Brunner, Rupa Narayan, Julia Foster, Amir T Fathi, Hanno Hock
Publikováno v:
The Oncologist. 27:82-86
BCR-ABL1 kinase inhibitors have improved the prognosis of Philadelphia-chromosome-positive (Ph+)-acute lymphoblastic leukemia (ALL). Ph-like (or BCR-ABL1-like) ALL does not express BCR-ABL1 but commonly harbors other genomic alterations of signaling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04d6069b5329e0f6f92acd2747e07497
https://doi.org/10.1093/oncolo/oyab052
https://doi.org/10.1093/oncolo/oyab052